Transcriptomic Signature Development

Transcriptomic Signature Development is the systematic process of identifying and validating a set of gene expression patterns that uniquely characterize a specific biological state or condition, distinguishing it from other molecular profiling approaches by focusing on reproducible, interpretable, and clinically or functionally relevant transcriptional markers.

102

Publications

6.9K

Citations

1.4K

Authors

540

Institutions

Publications per year

2017–2026

77

Authors

1.4K

  1. ND
    Nelson Dusetti

    Inserm, France

    5 publications · 245 citations

    5

    h-index

  2. AG
    Ajay Goel

    Baylor University Medical Center, United States

    5 publications · 267 citations

    5

    h-index

  3. JI
    Juan Iovanna

    Inserm, France

    5 publications · 245 citations

    5

    h-index

  4. AD
    Aurélien de Reyniès

    La Ligue Contre le Cancer, France

    4 publications · 246 citations

    4

    h-index

  5. PK
    Purvesh Khatri

    Stanford University, United States

    4 publications · 94 citations

    4

    h-index

1–5 of 1.4K

Venues

  1. Clinical Cancer Research

    5 publications · 256 citations

    5

    h-index

  2. Scientific Reports

    5 publications · 196 citations

    5

    h-index

  3. Archives of Toxicology

    2 publications · 71 citations

    2

    h-index

  4. Nature Communications

    2 publications · 88 citations

    2

    h-index

  5. Cancers

    2 publications · 63 citations

    2

    h-index

1–5